Stay updated on TTI-622 and Daratumumab Combo in Multiple Myeloma Clinical Trial
Sign up to get notified when there's something new on the TTI-622 and Daratumumab Combo in Multiple Myeloma Clinical Trial page.

Latest updates to the TTI-622 and Daratumumab Combo in Multiple Myeloma Clinical Trial page
- ChecktodayChange DetectedThe site footer now displays revision v3.8.1 instead of v3.8.0.SummaryDifference0.1%

- Check7 days agoChange DetectedThe record provides details of the TTI-622 and daratumumab hyaluronidase-fihj study for relapsed or refractory multiple myeloma, including its design, participant criteria, and outcome measures. The study is listed as completed and is no longer recruiting.SummaryDifference51%

- Check14 days agoChange DetectedThe footer revision label changes from v3.7.2 to v3.8.0; the page continues to show a 403 Forbidden message instead of the study record.SummaryDifference0.2%

- Check28 days agoChange DetectedA sitewide NIH notice about using “Super Intelligence” instead of “Artificial Intelligence” appears above the 403 error page. The site revision advances from v3.7.1 to v3.7.2.SummaryDifference1%

- Check42 days agoChange DetectedThe site footer revision changes from v3.7.0 to v3.7.1 while the page continues to display a 403 error.SummaryDifference0.2%

- Check49 days agoChange DetectedThe study record page now displays a 403 Forbidden error, indicating restricted access to the content. The page shows a minimal error layout with a 403 message and a Home link, preventing access to the trial details.SummaryDifference0.5%

Stay in the know with updates to TTI-622 and Daratumumab Combo in Multiple Myeloma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the TTI-622 and Daratumumab Combo in Multiple Myeloma Clinical Trial page.